DDD Partners LLC Increases Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT)

DDD Partners LLC raised its position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) by 2.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 800,922 shares of the company’s stock after purchasing an additional 17,225 shares during the period. DDD Partners LLC’s holdings in Adaptive Biotechnologies were worth $3,925,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of ADPT. ARK Investment Management LLC boosted its holdings in shares of Adaptive Biotechnologies by 11.3% in the 4th quarter. ARK Investment Management LLC now owns 12,806,513 shares of the company’s stock valued at $62,752,000 after buying an additional 1,297,205 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Adaptive Biotechnologies by 1.6% in the 3rd quarter. Vanguard Group Inc. now owns 12,249,042 shares of the company’s stock valued at $66,757,000 after buying an additional 196,555 shares in the last quarter. BlackRock Inc. boosted its holdings in shares of Adaptive Biotechnologies by 12.2% in the 3rd quarter. BlackRock Inc. now owns 10,119,409 shares of the company’s stock valued at $72,051,000 after buying an additional 1,098,301 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. boosted its holdings in shares of Adaptive Biotechnologies by 2.9% in the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 6,570,939 shares of the company’s stock valued at $35,812,000 after buying an additional 186,892 shares in the last quarter. Finally, Bellevue Group AG boosted its holdings in shares of Adaptive Biotechnologies by 59.8% in the 1st quarter. Bellevue Group AG now owns 3,145,293 shares of the company’s stock valued at $43,657,000 after buying an additional 1,176,862 shares in the last quarter. 99.17% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, insider Kyle Piskel sold 7,727 shares of the company’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $3.43, for a total transaction of $26,503.61. Following the completion of the sale, the insider now directly owns 123,318 shares of the company’s stock, valued at approximately $422,980.74. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, insider Kyle Piskel sold 7,727 shares of the company’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $3.43, for a total value of $26,503.61. Following the sale, the insider now owns 123,318 shares in the company, valued at approximately $422,980.74. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Chad M. Robins sold 48,673 shares of the stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $3.43, for a total transaction of $166,948.39. Following the sale, the chief executive officer now owns 2,576,701 shares in the company, valued at approximately $8,838,084.43. The disclosure for this sale can be found here. Insiders sold 124,307 shares of company stock valued at $428,090 in the last ninety days. Company insiders own 5.20% of the company’s stock.

Adaptive Biotechnologies Price Performance

Shares of Adaptive Biotechnologies stock opened at $2.89 on Thursday. The business has a 50 day moving average price of $3.74 and a 200 day moving average price of $4.39. The company has a market capitalization of $419.31 million, a P/E ratio of -1.85 and a beta of 1.27. Adaptive Biotechnologies Co. has a 1 year low of $2.61 and a 1 year high of $9.08.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings results on Wednesday, February 14th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.02. The company had revenue of $45.78 million during the quarter, compared to the consensus estimate of $50.15 million. Adaptive Biotechnologies had a negative return on equity of 53.65% and a negative net margin of 132.29%. As a group, research analysts expect that Adaptive Biotechnologies Co. will post -1.31 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. JPMorgan Chase & Co. decreased their price target on shares of Adaptive Biotechnologies from $11.00 to $8.00 and set an “overweight” rating for the company in a research note on Thursday, February 15th. The Goldman Sachs Group cut their price target on shares of Adaptive Biotechnologies from $11.00 to $5.00 and set a “neutral” rating for the company in a report on Friday, February 16th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $7.25.

Adaptive Biotechnologies Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.